Results 71 to 80 of about 70,790 (271)
Periodontitis and high phosphate intake alone or in combination adversely affect the kidney
Journal of Periodontology, EarlyView.Abstract Background Periodontitis and high phosphate (HP) intake can negatively affect the kidney in the presence of renal disease. This study aimed to evaluate the effects of periodontitis or HP intake, either alone or concurrently, on the periodontal tissue and the kidney under normal renal conditions.
Ae Ri Kim +4 more
wiley +1 more source
Update on the use of etanercept across a spectrum of rheumatoid disorders
Biologics: Targets & Therapy, 2008 Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis
Bernard Combe
doaj
Pediatric Rheumatology Online Journal, 2017 Background The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.
Ekaterina I. Alexeeva +11 more
doaj +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa +2 more
wiley +1 more source
Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All
Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic +2 more
wiley +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son +10 more
wiley +1 more source
The structure-function relationship of disulfide bonds in etanercept
Scientific Reports, 2017 Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) revealed a ...
William C. Lamanna +10 more
semanticscholar +1 more source
Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study
JEADV Clinical Practice, EarlyView.ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu +2 more
wiley +1 more source
Health-related quality of life of patients with rheumatoid arthritis on tocilizumab, adalimumab, and etanercept in Saudi Arabia: a single-center cross-sectional study [PDF]
, 2023 Amjad M. Alotaibi +5 more
openalex +1 more source
Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon +5 more
wiley +1 more source